Jeil Pharm (002620) — Cash Flow-to-Debt Ratio
Jeil Pharm (002620) has a Cash Flow-to-Debt Ratio of 0.00x as of December 2025, meaning its operating cash flow of ₩1.97 Billion could theoretically repay 0% of its total liabilities (₩407.55 Billion) in one year. See how much free cash does Jeil Pharm generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jeil Pharm Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Jeil Pharm across 13 annual periods. Also explore net asset momentum of Jeil Pharm to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Jeil Pharm (2011–2025)
Year-by-year debt coverage analysis for Jeil Pharm. For market capitalisation and broader financial context, see 002620 stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.00x | ₩390.26 Million | ₩407.55 Billion | ▼ -90.4% |
| 2024 | 0.01x | ₩4.54 Billion | ₩453.04 Billion | ▲ +208.5% |
| 2023 | -0.01x | ₩-4.42 Billion | ₩477.81 Billion | ▲ +80.2% |
| 2022 | -0.05x | ₩-20.80 Billion | ₩445.88 Billion | ▼ -236.5% |
| 2021 | 0.03x | ₩13.40 Billion | ₩392.11 Billion | ▲ +156.0% |
| 2020 | -0.06x | ₩-23.67 Billion | ₩388.11 Billion | ▼ -187.9% |
| 2019 | 0.07x | ₩25.22 Billion | ₩363.44 Billion | ▲ +768.0% |
| 2018 | -0.01x | ₩-3.43 Billion | ₩330.51 Billion | ▼ -104.8% |
| 2017 | 0.22x | ₩5.92 Billion | ₩27.15 Billion | ▲ +360.9% |
| 2016 | 0.05x | ₩11.36 Billion | ₩239.91 Billion | ▲ +251.6% |
| 2015 | 0.01x | ₩2.74 Billion | ₩203.78 Billion | ▲ +151.0% |
| 2012 | -0.03x | ₩-3.94 Billion | ₩149.36 Billion | ▼ -117.1% |
| 2011 | 0.15x | ₩23.63 Billion | ₩152.74 Billion | — |